Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abivax SA ( (FR:ABVX) ) has shared an announcement.
Abivax has released its provisional financial communication schedule for 2025, outlining key dates for the disclosure of its annual and quarterly financial results, as well as its Annual General Meeting. This announcement is crucial for stakeholders and investors as it sets expectations for the company’s financial transparency and reporting throughout the year, which could influence investor confidence and stock performance.
More about Abivax SA
Abivax is a clinical-stage biotechnology company dedicated to developing therapies that leverage the body’s natural regulatory mechanisms to manage chronic inflammatory diseases. Headquartered in both France and the United States, Abivax’s leading drug candidate is obefazimod (ABX464), which is currently in phase 3 clinical trials for treating moderate to severe active ulcerative colitis.
YTD Price Performance: -11.08%
Average Trading Volume: 802
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €386.5M
For detailed information about ABVX stock, go to TipRanks’ Stock Analysis page.
